Diabetes & Metabolism Journal

Hak Yeon Bae (Bae HY)

3 Articles

Others
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin: Jong Ho Kim, Sang Soo Kim, Hong Sun Baek, In Kyu Lee, Dong Jin Chung, Ho Sang Sohn, Hak Yeon Bae, Mi Kyung Kim, Jeong Hyun Park, Young Sik Choi, Young Il Kim, Jong Ryeal Hahm, Chang Won Lee, Sung Rae Jo, Mi Kyung Park, Kwang Jae Lee, In Joo Kim; Diabetes Metab J. 2016;40(3):230-239. Published online April 5, 2016; DOI: https://doi.org/10.4093/dmj.2016.40.3.230

6,225 View
57 Download
13 Web of Science
13 Crossref

Abstract PDF Supplementary Material PubReader

Background

We compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes.

Methods

The present study was a multicenter, randomized, active-controlled investigation comparing the effects of vildagliptin and pioglitazone in Korean patients receiving a stable dose of metformin but exhibiting inadequate glycemic control. Each patient underwent a 16-week treatment period with either vildagliptin or pioglitazone as an add-on treatment to metformin.

Results

The mean changes in HbA1c levels from baseline were –0.94% in the vildagliptin group and –0.6% in the pioglitazone group and the difference between the treatments was below the non-inferiority margin of 0.3%. The mean changes in postprandial plasma glucose (PPG) levels were –60.2 mg/dL in the vildagliptin group and –38.2 mg/dL in the pioglitazone group and these values significantly differed (P=0.040). There were significant decreases in the levels of total, low density lipoprotein, high density lipoprotein (HDL), and non-HDL cholesterol in the vildagliptin group but increases in the pioglitazone group. The mean change in body weight was –0.07 kg in the vildagliptin group and 0.69 kg in the pioglitazone group, which were also significantly different (P=0.002).

Conclusion

As an add-on to metformin, the efficacy of vildagliptin for the improvement of glycemic control is not inferior to that of pioglitazone in Korean patients with type 2 diabetes. In addition, add-on treatment with vildagliptin had beneficial effects on PPG levels, lipid profiles, and body weight compared to pioglitazone.

Citations

Citations to this article as recorded by

Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
Swetha R. Reghunath, Muhammed Rashid, Viji Pulikkel Chandran, Girish Thunga, K.N. Shivashankar, Leelavathi D. Acharya
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(7): 102790. CrossRef
Efficacy and safety of evogliptin in patients with type 2 diabetes and non‐alcoholic fatty liver disease: A multicentre, double‐blind, randomized, comparative trial
Eugene Han, Ji Hye Huh, Eun Y. Lee, Ji C. Bae, Sung W. Chun, Sung H. Yu, Soo H. Kwak, Kyong S. Park, Byung‐Wan Lee
Diabetes, Obesity and Metabolism.2022; 24(4): 752. CrossRef
A double‐blind, Randomized controlled trial on glucose‐lowering EFfects and safety of adding 0.25 or 0.5 mg lobeglitazone in type 2 diabetes patients with INadequate control on metformin and dipeptidyl peptidase‐4 inhibitor therapy: REFIND study
Soree Ryang, Sang Soo Kim, Ji Cheol Bae, Ji Min Han, Su Kyoung Kwon, Young Il Kim, Il Seong Nam‐Goong, Eun Sook Kim, Mi‐kyung Kim, Chang Won Lee, Soyeon Yoo, Gwanpyo Koh, Min Jeong Kwon, Jeong Hyun Park, In Joo Kim
Diabetes, Obesity and Metabolism.2022; 24(9): 1800. CrossRef
The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort
Gilberto Vargas-Alarcón, María del Carmen González-Salazar, Christian Vázquez-Vázquez, Adrián Hernández-Díaz Couder, Fausto Sánchez-Muñoz, Juan Reyes-Barrera, Sergio A. Criales-Vera, Marco Sánchez-Guerra, Citlalli Osorio-Yáñez, Rosalinda Posadas-Sánchez
Frontiers in Genetics.2021;[Epub] CrossRef
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
A.J. Scheen
Diabetes & Metabolism.2020; 46(3): 186. CrossRef
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Min Kyong Moon
The Journal of Korean Diabetes.2018; 19(1): 23. CrossRef
Comparative Cardiovascular Risks of Dipeptidyl Peptidase-4 Inhibitors: Analyses of Real-world Data in Korea
Kyoung Hwa Ha, Bongseong Kim, Hae Sol Shin, Jinhee Lee, Hansol Choi, Hyeon Chang Kim, Dae Jung Kim
Korean Circulation Journal.2018; 48(5): 395. CrossRef
Safety and efficacy of low dose pioglitazone compared with standard dose pioglitazone in type 2 diabetes with chronic kidney disease: A randomized controlled trial
Bancha Satirapoj, Khanin Watanakijthavonkul, Ouppatham Supasyndh, Stephen L Atkin
PLOS ONE.2018; 13(10): e0206722. CrossRef
Combination therapy of oral hypoglycemic agents in patients with type 2 diabetes mellitus
Min Kyong Moon, Kyu Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
The Korean Journal of Internal Medicine.2017; 32(6): 974. CrossRef
Combination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Min Kyong Moon, Kyu-Yeon Hur, Seung-Hyun Ko, Seok-O Park, Byung-Wan Lee, Jin Hwa Kim, Sang Youl Rhee, Hyun Jin Kim, Kyung Mook Choi, Nan-Hee Kim
Diabetes & Metabolism Journal.2017; 41(5): 357. CrossRef
Efficacy and safety of adding evogliptin versus sitagliptin for metformin‐treated patients with type 2 diabetes: A 24‐week randomized, controlled trial with open label extension
Sang‐Mo Hong, Cheol‐Young Park, Dong‐Min Hwang, Kyung Ah Han, Chang Beom Lee, Choon Hee Chung, Kun‐Ho Yoon, Ji‐Oh Mok, Kyong Soo Park, Sung‐Woo Park
Diabetes, Obesity and Metabolism.2017; 19(5): 654. CrossRef
Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
The Korean Journal of Internal Medicine.2017; 32(6): 947. CrossRef
Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
Diabetes & Metabolism Journal.2017; 41(5): 337. CrossRef

Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J 2013;37:423-8): Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim; Diabetes Metab J. 2014;38(2):160-161. Published online April 18, 2014; DOI: https://doi.org/10.4093/dmj.2014.38.2.160

3,897 View
34 Download
5 Web of Science
5 Crossref

PDF PubReader

Citations

Citations to this article as recorded by

The unique association between the level of plateletcrit and the prevalence of diabetic kidney disease: a cross-sectional study
Shuwu Wei, Xinyu Pan, Yao Xiao, Ruishuang Chen, Junping Wei
Frontiers in Endocrinology.2024;[Epub] CrossRef
Impact of Uncontrolled Diabetes Mellitus on Blood Cells Indices and Plasma Components in Patients Without Nephropathy
Hisham Ali Waggiallah, Hala Elsir Khair, Rania Saad Suliman, Humood Al Shmrany, Elturabi Elsayed Elkhider, Mudathir Mohamed Ahmed Eltayeb, Nermen Abdelftah Mohamed Ma, Yousif Mohammed Elmosaad
Pakistan Journal of Biological Sciences.2023; 26(5): 279. CrossRef
Effects of statin therapy on mean platelet volume in patients with risk of cardiovascular diseases: a systematic review and meta-analysis
Shuaifei Ji, Babo Zhang, Xianda Wang, Heng Shi, Lixin Yu, Xiaocheng Wang
Bioscience Reports.2019;[Epub] CrossRef
The relationship between mean platelet volume and diabetic retinopathy: a systematic review and meta-analysis
ShuaiFei Ji, Jie Zhang, XiuDe Fan, XiQiang Wang, XiaoNa Ning, BaBo Zhang, Heng Shi, Hong Yan
Diabetology & Metabolic Syndrome.2019;[Epub] CrossRef
Platelets volume indexes and cardiovascular risk factors
Thaís Resende Batista, Roberta Carvalho de Figueiredo, Danyelle Romana Alves Rios
Revista da Associação Médica Brasileira.2018; 64(6): 554. CrossRef

Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus: Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim; Diabetes Metab J. 2013;37(6):423-428. Published online December 12, 2013; DOI: https://doi.org/10.4093/dmj.2013.37.6.423

5,570 View
78 Download
28 Crossref

Abstract PDF PubReader

Atherothrombotic complications are important causes of morbidity and mortality in diabetic patients. Diabetes has been considered to be a prothrombotic status. Several factors contribute to the prothrombotic condition, such as increasing coagulation, impaired fibrinolysis, endothelial dysfunction, and platelet hyperreactivity. Among the factors that contribute to the prothrombotic status in diabetes, altered platelet function plays a crucial role. Although understanding platelet function abnormalities in diabetes still remains as a challenge, more attention should be focused on platelet function for effective management and the prediction of atherothrombotic events in diabetic patients. This review will provide an overview on the current status of knowledge of platelet function abnormalities and clinical marker of platelet hyperreactivity in patients with diabetes.

Citations

Citations to this article as recorded by

Single nucleotide polymorphism rs7961894, platelet morphological parameters and lipid profile in children with type 1 diabetes: a potential relationship
Mahmoud A. El-Hawy, Shimaa Abdelsattar, Hanan M. Bedair, Doaa Z. Elsaady, Ahmed S. Abo Hola
European Journal of Pediatrics.2024; 183(10): 4385. CrossRef
Prediction of type 2 diabetes mellitus using hematological factors based on machine learning approaches: a cohort study analysis
Amin Mansoori, Toktam Sahranavard, Zeinab Sadat Hosseini, Sara Saffar Soflaei, Negar Emrani, Eisa Nazar, Melika Gharizadeh, Zahra Khorasanchi, Sohrab Effati, Mark Ghamsary, Gordon Ferns, Habibollah Esmaily, Majid Ghayour Mobarhan
Scientific Reports.2023;[Epub] CrossRef
Platelet P2Y1 receptor exhibits constitutive G protein signaling and β-arrestin 2 recruitment
Agnès Ribes, Cédric Garcia, Marie-Pierre Gratacap, Evi Kostenis, Laurent O. Martinez, Bernard Payrastre, Jean-Michel Sénard, Céline Galés, Véronique Pons
BMC Biology.2023;[Epub] CrossRef
Sex differences in the relationship between platelet count and type 2 diabetes risk in community‐dwelling adults: Longitudinal findings over 14 years
Eun Kyeong Yun, In‐Ho Seo, Hye Sun Lee, So‐Young Seol, Yong‐Jae Lee
Diabetes/Metabolism Research and Reviews.2023;[Epub] CrossRef
Platelet Glycoprotein-Ib (GPIb) May Serve as a Bridge between Type 2 Diabetes Mellitus (T2DM) and Atherosclerosis, Making It a Potential Target for Antiplatelet Agents in T2DM Patients
Muttia Amalia, Meidi Utami Puteri, Fadlina Chany Saputri, Rani Sauriasari, Bambang Widyantoro
Life.2023; 13(7): 1473. CrossRef
Effect of oral versus parenteral vitamin D3 supplementation on nuclear factor-κB and platelet aggregation in type 2 diabetic patients
Esraa Habiba, Samia Ali, Yehia Ghanem, Ola Sharaki, Wafaa Hewedy
Canadian Journal of Physiology and Pharmacology.2023; 101(11): 610. CrossRef
Characteristics of cerebral ischemic stroke based on moyamoya disease and atherosclerosis-associated intracranial arterial stenosis
Zhiying Chen, Xiaoqin Wu, Da Zhou, Shuling Shang, Yuchuan Ding, Xunming Ji, Ran Meng
Neurological Sciences.2022; 43(2): 1087. CrossRef
Basic Coagulation Profiles and Platelet Parameters Among Adult Type 1 and Type 2 Diabetes Patients at Dessie Referral Hospital, Northeast Ethiopia: Comparative Cross-Sectional Study
Hussen Ebrahim, Fikir Asrie, Zegeye Getaneh
Journal of Blood Medicine.2021; Volume 12: 33. CrossRef
Magnetic fields as a potential therapy for diabetic wounds based on animal experiments and clinical trials
Huanhuan Lv, Junyu Liu, Chenxiao Zhen, Yijia Wang, Yunpeng Wei, Weihao Ren, Peng Shang
Cell Proliferation.2021;[Epub] CrossRef
Diabetes and hypertension: Pivotal involvement of purinergic signaling
Karine Paula Reichert, Milagros Fanny Vera Castro, Charles Elias Assmann, Nathieli Bianchin Bottari, Vanessa Valéria Miron, Andréia Cardoso, Naiara Stefanello, Vera Maria Melchiors Morsch, Maria Rosa Chitolina Schetinger
Biomedicine & Pharmacotherapy.2021; 137: 111273. CrossRef
The hemostatic parameters in pregnant women with different types of diabetes mellitus
R. V. Kapustin, E. V. Kopteeva, O. N. Arzhanova, A. V. Tiselko, N. Е. Androsova, T. I. Oparina
Diabetes mellitus.2021; 24(3): 251. CrossRef
A study of activated platelet by flow cytometry in diabetic patients with peripheral arterial disease
Maisa A. Abdel Wahab, Shaymaa A. Mohammed, Inass H. Ahmad, Salwa I. Elshennawy, Sadek Mostafa
Al-Azhar Assiut Medical Journal.2021; 19(3): 395. CrossRef
Comparison of the progressive changes in hemogram parameters of normal glycemic and gestational diabetic patients throughout the first two trimesters and predictive ability of these indices for gestational diabetes mellitus
Pelin AYTAN, Seyran BOZKURT BABUŞ, Özde SAKARYA, Revan Sabri ÇİFTÇİ, Kasım AKAY, Hakan AYTAN
Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi.2020; 17(4): 533. CrossRef
A Pilot Study on the Effect of Anti-Thrombopoietin Antibody on Platelet Count in Patients with Type 2 Diabetes
Takuya Fukuda, Masahide Hamaguchi, Takafumi Osaka, Yoshitaka Hashimoto, Emi Ushigome, Mai Asano, Masahiro Yamazaki, Eriko Fukuda, Kei Yamaguchi, Koji Ogawa, Naoki Goshima, Michiaki Fukui
Molecules.2020; 25(7): 1667. CrossRef
Patient with diabetes after acute coronary event. How to improve forecast?
O. L. Barbarash
Medical alphabet.2019; 1(3): 6. CrossRef
Enhanced Platelet Sensitivity to IGF-1 in Patients with Type 2 Diabetes Mellitus
N. Gligorijevic, D. Robajac, O. Nedic
Biochemistry (Moscow).2019; 84(10): 1213. CrossRef
Comprehensive Quality Control of the Regenerative Therapy Using Platelet Concentrates: The Current Situation and Prospects in Japan
Tomoyuki Kawase, Kazuhiro Okuda
BioMed Research International.2018; 2018: 1. CrossRef
Changes in platelet morphology indices in relation to duration of disease and glycemic control in children with type 1 diabetes mellitus
Vybhav Venkatesh, Rakesh Kumar, Dinesh Kumar Varma, Prateek Bhatia, Jaivinder Yadav, Devi Dayal
Journal of Diabetes and its Complications.2018; 32(9): 833. CrossRef
Quantifying Platelet Margination in Diabetic Blood Flow
Hung-Yu Chang, Alireza Yazdani, Xuejin Li, Konstantinos A.A. Douglas, Christos S. Mantzoros, George Em Karniadakis
Biophysical Journal.2018; 115(7): 1371. CrossRef
Redox Proteomics and Platelet Activation: Understanding the Redox Proteome to Improve Platelet Quality for Transfusion
Giona Sonego, Mélanie Abonnenc, Jean-Daniel Tissot, Michel Prudent, Niels Lion
International Journal of Molecular Sciences.2017; 18(2): 387. CrossRef
Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
Amanda J. Unsworth, Alexander P. Bye, Dionne S. Tannetta, Michael J.R. Desborough, Neline Kriek, Tanya Sage, Harriet E. Allan, Marilena Crescente, Parveen Yaqoob, Timothy D. Warner, Chris I. Jones, Jonathan M. Gibbins
Arteriosclerosis, Thrombosis, and Vascular Biology.2017; 37(8): 1482. CrossRef
Aspirin in the prevention of cardiovascular events in patients with diabetes
David S. H. Bell
Postgraduate Medicine.2016; 128(2): 180. CrossRef
ROLE OF NITRIC OXIDE METABOLITES WITHIN THE IMPACT OF THE SUB-TOXIC SUCCINAMIDES DOSES ON STATE OF HEMOSTASIS
I.А. Palagina, M.Y. Kudria, О.S. Lаlymеnkо
Fiziolohichnyĭ zhurnal.2016; 62(6): 34. CrossRef
Influence of genetic variations in platelet glycoproteins and eNOS in the development of arterial ischaemia of lower limbs in type 2 diabetes mellitus patients
Virginia Carvalhais, Ema Ruivães, Luis Bernardo Pina-Cabral, Bárbara Mesquita, Flávio Oliveira, Maria Céu Monteiro, Maria Begoña Criado
The Foot.2016; 29: 42. CrossRef
Circulating endothelial progenitor cells and angiogenic factors in diabetes complicated diabetic foot and without foot complications
Arleta Kulwas, Ewelina Drela, Wiesław Jundziłł, Barbara Góralczyk, Barbara Ruszkowska-Ciastek, Danuta Rość
Journal of Diabetes and its Complications.2015; 29(5): 686. CrossRef
Cerebrovascular diseases: perspectives of pathogenetic metabolic haemangiocorrective treatment
M. M. Tanashyan, O. V. Lagoda, K. V. Antonova
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova.2015; 115(9): 70. CrossRef
Letter: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
Cengiz Beyan, Esin Beyan
Diabetes & Metabolism Journal.2014; 38(2): 158. CrossRef
Response: Clinical Marker of Platelet Hyperreactivity in Diabetes Mellitus (Diabetes Metab J2013;37:423-8)
Jin Hwa Kim, Hak Yeon Bae, Sang Yong Kim
Diabetes & Metabolism Journal.2014; 38(2): 160. CrossRef

Author index